Profil
Thomas Lander formerly worked at CureVac SE, as Managing Director, Allergy Therapeutics Plc, as Independent Non-Executive Director from 2012 to 2017, vasopharm GmbH, as Director-Supervisory Board, Tuebingen Scientific Medical GmbH, as Managing Director, Lipid Therapeutics GmbH, as Non-Executive Director, Merck KGaA, as Chief Medical Officer, Novo Nordisk A, as Principal, and Boehringer Ingelheim AB, as Principal.
Anciens postes connus de Thomas Lander
| Sociétés | Poste | Fin |
|---|---|---|
| ALLERGY THERAPEUTICS PLC | Directeur/Membre du Conseil | 30/06/2017 |
| MERCK KGAA | Directeur Technique/Scientifique/R&D | - |
vasopharm GmbH
 vasopharm GmbH Pharmaceuticals: MajorHealth Technology vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany. | Directeur/Membre du Conseil | - |
Tuebingen Scientific Medical GmbH
 Tuebingen Scientific Medical GmbH Medical SpecialtiesHealth Technology Tuebingen Scientific Medical GmbH develops, produces and markets instruments and accessories for minimally invasive surgery. The company was founded by Marc O. Schurris in 2001 and is headquartered in Tübingen, Germany. | Corporate Officer/Principal | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK KGAA | Health Technology |
| NOVO NORDISK A/S | Health Technology |
| ALLERGY THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 5 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
vasopharm GmbH
vasopharm GmbH Pharmaceuticals: MajorHealth Technology vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany. | Health Technology |
Tuebingen Scientific Medical GmbH
Tuebingen Scientific Medical GmbH Medical SpecialtiesHealth Technology Tuebingen Scientific Medical GmbH develops, produces and markets instruments and accessories for minimally invasive surgery. The company was founded by Marc O. Schurris in 2001 and is headquartered in Tübingen, Germany. | Health Technology |
Boehringer Ingelheim AB
 Boehringer Ingelheim AB Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim AB develops, produces, markets and sells pharmaceutical products. The firm also provides research, development, manufacturing and marketing services in the therapeutic field of human and veterinary medicine. The company was founded in 1967 is headquartered in Stockholm, Germany. | Health Technology |
Lipid Therapeutics GmbH
 Lipid Therapeutics GmbH Medical/Nursing ServicesHealth Services Lipid Therapeutics GmbH develops therapies for inflammatory diseases of the digestive system. Its product is LT-02, a delayed release of Phosphatidylcholine, for the treatment of Ulcerative colitis based on the preclinical and clinical work conducted by Prof. Stremmel from the University Hospital Heidelberg. The company was founded in 2008 and is headquartered in Heidelberg, Germany. | Health Services |
